Is there a role for consensus guidelines for P. jiroveci pneumonia prophylaxis in immunosuppressed patients with rheumatic diseases?

Journal of Rheumatology

Volumn 37, Issue 4, 2010, Pages 686-688

  Stamp, Lisa K ^a,b   Hurst, Miriam ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; AZATHIOPRINE; CD20 ANTIBODY; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; METHOTREXATE; PENTAMIDINE; PREDNISOLONE; TUMOR NECROSIS FACTOR INHIBITOR;

AMINOTRANSFERASE BLOOD LEVEL; DISEASE ASSOCIATION; EDITORIAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LEUKOPENIA; LIVER TOXICITY; MORBIDITY; MORTALITY; NAUSEA; OUTCOME ASSESSMENT; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RASH; REMISSION; RHEUMATIC DISEASE; RISK FACTOR; SIDE EFFECT; SKIN DISEASE; TREATMENT INDICATION; TREATMENT RESPONSE;

HUMANS; IMMUNOCOMPROMISED HOST; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; PRACTICE GUIDELINES AS TOPIC; RHEUMATIC DISEASES;

EID: 77950670409     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.091426     Document Type: Editorial

References (19)

1. Sepkowitz K. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis 2002;34:1098-1107 (Pubitemid 34289683)
2. Dykewics D. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001;33:139-144 (Pubitemid 32643326)
3. EBPG Expert Group in Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.7.1 Late infections. Pneumocystis carinii pneumonia. Nephrol Dial Transplant 2002;17:36-39
4. Cettomai D, Gelber A, Christopher-Stine L. A survey of rheumatologists' practice for prescribing Pneumocystis prophylaxis. J Rheumatol 2010;37:792-799
5. Falagas M, Manta K, Betsi G, Pappas G. Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review. Clin Rheumatol 2007;26:663-670 (Pubitemid 46554069)
6. Ward M, Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases. The role of hospital experience in diagnosis and mortality. Arthritis Rheum 1999;42:780-789
7. Yale S, Limper A. Pneumocystis carinii Pneumonia in patients without acquired immunodeficiency syndrome: Associated illnesses and prior cortiocosteroid therapy. Mayo Clin Proc 1996;71:5-13. (Pubitemid 26021784)
8. McLean-Tooke A, Aldridge C, Waugh S, Spickett G, Kay L. Methotrexate, rheumatoid arthritis and infection risk - what is the evidence? Rheumatology 2009;48:867-871
9. Gerrard J. Pneumocystis carinii pneumonia in HIV-negative immunocompromised adults. Med J Aust 1995;162:233-235
10. Sowden E, Carmichael A. Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: A strategy for prevention. BMC Infect Dis 2004;4:42-47 (Pubitemid 39615386)
11. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H, et al. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009;58(RR-4):1-207; quiz CE1-4.
12. Lertnawapan R, Totemchokchyakarn K, Nantiruj K, Janwityanujit S. Risk factors of Pneumocystis jiroveci pneumonia in patients with systemic lupus erythematosus. Rheumatol Int 2009;29:491-496
13. Iikuni N, Kitahama M, Ohta S, Okamoto H, Kamatani N, Nishinarita M. Evaluation of Pneumocystis pneumonia infection risk factors in patients with connective tissue disease. Mod Rheumatol 2006;16:282-288 (Pubitemid 44575253)
14. Mansharamani N, Balachandran D, Vernovsky I, Garland R, Koziel H. Peripheral blood CD4+ T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest 2000;118:712-720
15. Mori S, Cho I, Sugimoto M. A followup study of asymptomatic carriers of Pneumocystis jiroveci during immunosuppressive therapy for rheumatoid arthritis. J Rheumatol 2009;36:1600-1605
16. Hughes W, Kuhn S, Chaudhary S, Feldman S, Verzosa M, Aur R, et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. New Engl J Med 1977;297:1419-1426
17. Wormser G, Horowitz H, Duncanson F, Forseter G, Javaly K, Alampur S, et al. Low-dose intermittent trimethoprim-sulfame-thoxazole for prevention of Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. Arch Intern Med 1991;151:688-692
18. Stegeman C, Tervaert J, de Jong P, Kallenberg C. Trimethoprim- sulfamethoxazole (Co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. New Engl J Med 1996;335:16-20. (Pubitemid 26230808)
19. Langford C, Talar-Williams C, Barron K, Sneller M. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 2003;114:463-469 (Pubitemid 36515108)